Buch, Englisch, 104 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 189 g
Buch, Englisch, 104 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 189 g
Reihe: SpringerBriefs in Biochemistry and Molecular Biology
ISBN: 978-3-0348-0401-1
Verlag: Springer
This Brief firstly defines gene therapy, and places lentivectors within this fascinating therapeutic strategy. Then follows a comprehensive description of the development of retroviral and lentiviral vectors and how to specifically target distinct cell types and tissues. The authors also discuss the application of lentivector gene therapy for the treatment of cancer and autoimmune diseases, ending with the application of lentivectors in human gene therapy clinical trials.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Humangenetik
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Medizinische Mikrobiologie & Virologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Gentherapie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
Weitere Infos & Material
1 Introduction to gene therapy.- 1.1 The concept of gene therapy.- 1.2 Origins of gene therapy.- 1.3 Gene therapy in the 1970s.- 1.4 Gene therapy in the 1980s.- 1.5 The breakthroughs in gene therapy from the 1990s and 2000s.- 1.6 Current human gene therapy and lentiviral vectors.- 1.7. Concluding remarks.- 2 Development of retroviral and lentiviral vectors.- 2.1 Retrovirus biology.- 2.2 Vectors based on ? -retroviruses.- 2.3 Vectors based on lentiviruses.- 2.4 Summary and conclusions.- 3 Cell and tissue gene targeting with lentiviral vectors.- 3.1 Introduction.- 3.2 Modification of lentivector tropism by pseudotyping (surface targeting).- 3.3 Transcriptional targeting.- 3.4 Post-transcriptional targeting.- 3.5 Conclusions.- 4 Immunomodulation by genetic modification using lentiviral vectors.- 4.1 Introduction to genetic immunotherapy.- 4.2 Lentivector gene therapy for immunization.- 4.3 Lentivector gene therapy for the treatment of autoimmune disease.- 4.4 Conclusions.- 5 Clinical grade lentiviral vectors.- 5.1 Introduction.- 5.2 Good manufacturing practise guidelines and clinical grade vector preparations.- 5.3 Scaling-up lentivector production for clinical application.- 5.4 Purity of clinical grade lentivectors.- 5.5 Biosafety.- 5.6 Final considerations and conclusions.- 6 Human gene therapy with retrovirus and lentivirus vectors.- 6.1 Introduction.- 6.2 Correction of Severe Combined Immunodeficiency-X1.- 6.3 Correction of X-linked chronic granulomatous disease.- 6.4 Correction of X-linked adrenoleukodystrophy.- 6.5 Correction of b-thalassaemia.- 6.6 Correction of Wiscott-Aldrich syndrome.- 6.7 Conclusions and final considerations.